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Purpose: To establish the method for the analysis of rifampin quinone and hydrazone in fixed-
dose combination tablets (FDC) containing rifampicin with or without sodium ascorbate as an additive.    
Methods:  The International Pharmacopoeial (IP) method for the estimation of rifampin quinone in FDC 
was modified. The extraction solvent (methanol/buffer mixture) of the IP method was replaced with ethyl 
acetate, in order to stabilize rifampin quinone in sample solutions of FDC containing sodium ascorbate 
as an ingredient.  
Results:  Rifampin quinone in FDC samples containing sodium ascorbate, which is not detectable in the 
IP method, was found to be 1.15 % (4-FDC), 1.52 % (3-FDC) and 1.60 % (2-FDC) using the modified 
method.  Recovery of rifampin quinone in spiked samples of FDCs was practically nil in IP method 
whereas the recovery was 99.95%, 99.39 and 99.02 % for 4–FDC, 3-FDC and 2-FDC, respectively. 
Conclusion: This modified method was suitable for the determination of rifampin quinone in fixed-dose 
formulations of rifampin both in the presence and absence of sodium ascorbate. The method is specific, 
precise, accurate, robust, rugged and gives a linear response for the quantitative estimation of rifampin 
quinone and hydrazone in fixed-dose combination tablets containing rifampin.  
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INTRODUCTION 
 
Fixed-dose combinations (FDC) of rifampin 
with other drugs, such as isoniazid (INH), 
pyrazinamide and ethambutal hydrochloride, 
is widely used for the treatment of 
tuberculosis. The International Pharma-
copoeia (IP) has published monographs for 
some fixed-dose combinations which include 
related substances test.  Some methods for 
estimation of the rifampin-related substances 
have been published in the literature [1-4]. 
From a formulation point of view, it is of 
paramount importance to keep these 
impurities within the specified limits [5,6]. 
Amongst the impurities of rifampin are 
rifampin quinone, which is an impurity formed 
from rifampicin by the process of oxidation [7-
9], and anti–oxidants such as sodium 
ascorbate, are used in the tablets to control 
the formation of rifampin quinone during 
storage of the tablets.   
 
The solvent mixture of methanol and buffer 
used in IP method for rifampin-related 
substances test in FDC rifampicin tablets is 
capable of dissolving sodium ascorbate and 
rifampin. Therefore, when this method is 
used for tablets containing sodium ascorbate 
as an additive, the sodium ascorbate which 
comes into solution in the sample preparation 
aids the conversion of rifampin quinone to 
rifampin in the sample preparation solution. 
On the basis of experiments to estimate 
rifampin quinone in FDCs containing sodium 
ascorbate using IP method at our laboratory, 
it was inferred that although rifampin quinone 
may be present in the tablet, IP method may 
not be able to accurately quantify this 
impurity since it gets converted to rifampin in 
the sample solution when sodium ascorbate 
is present. Therefore, the objective of this 
study was to substitute the extraction solvent 
of the IP method with another solvent in order 







Reagents and materials 
 
The reference standards - Rifampin USP 
(99.6 % pure) and Rifampin Quinone USP 
(98.6 % pure) were procured from Sandoz, 
India while 3-(isonicotinoylhydrazinomethyl) 
rifampicin [hydrazone] (95.5 % pure) was 
obtained from National Institute for 
Pharmaceutical Education and Research, 
India. Other materials used include 
potassium dihydrogen phosphate, ethyl 
acetate (analytical reagent grade, Qualigens, 
India), sodium hydroxide pellets (reagent 
grade) and methanol (HPLC grade, Merck, 
India). Water - purified with Millipore water 
system (Elix 10 C model) - was used for the 
preparation of buffer and sodium hydroxide 
solution. PTFE membrane filters (Syringe 
filter – 25 mm GD/X- Whatman, 0.45 µ) were 
used for the filtration of standard and sample 
solutions. Cellulose acetate filter (0.45 µ, 
Sartorium stedim) was used for the filtration 




A Waters high performance liquid 
chromatographic (HPLC) system equipped 
with a 2695 solvent delivery system, Waters 
auto injector, thermostatted column 
compartment and Waters 2998 photo diode 
array detector were used for the experiment. 
The samples were analysed using a Kromasil 
column (Akzo Nobel, a C-18 column of 
250mm x 4.6mm i.d., 5 µ particle size). A 
mixture of buffer and methanol in a ratio of 
60:40 (v/v) was used as the mobile phase. 
The buffer for the mobile phase was prepared 
by dissolving about 1.36 g of potassium 
dihydrogen phosphate in 900 mL of water, 
adjusting the pH to 7.00 ± 0.05 using 0.1M 
sodium hydroxide and then making up the 
volume to 1000 mL with water. The buffer 
and methanol mixture was degassed by 
sonication and filtered through a 0.45 µ 
cellulose acetate membrane filter.  
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Preparation of standard rifampin solution 
(Solution 1)   
 
About 2.5 mg of rifampin powder was 
accurately weighed and transferred to a dry 
10 mL volumetric flask. Ethyl acetate (7 mL) 
was added and the solution sonicated to 
dissolve the substance. The volume was then 
made up to 10ml with ethyl acetate. Out of 
this, 1 mL was diluted to 5 mL in a dry 
volumetric flask using ethyl acetate. Again, 1 
mL of this solution was diluted to 5 mL using 
a diluent (pH 7.0 buffer: methanol, 60:40 v/v) 
in a 5ml volumetric flask to obtain a 
concentration of 10 µg/mL of rifampin.  
 
Solution for system suitability (Solution 2)  
 
About 2.5 mg of 3-(isonicotinoylhydra-
zinomethyl) rifampicin, 2 mg of rifampin 
quinone and 2.5 mg of rifampin were 
accurately weighed and transferred to a dry 
10 mL volumetric flask. About 7 mL of ethyl 
acetate was added and the solution was 
sonicated to dissolve the substances. The 
volume was then made up to 10 mL with 
ethyl acetate. Out of this, 1 mL of this solution 
was transferred to a 5 mL dry volumetric flask 
and made up to volume with ethyl acetate. 
Again, 1 mL of this solution was diluted to 5 
mL using a diluent (pH 7.0 buffer: methanol, 
60:40 v/v) in a 5 mL volumetric flask to obtain 
a concentrations of 10 µg of rifampin, 10 µg 
of 3-(isonicotinoylhydrazinomethyl) rifampicin  
and 8 µg of rifampin quinone, each per mL.  
 
Preparation of test solutions as per 
proposed method (Solutions 3 - 5) 
 
Twenty 4-FDC tablets (i.e., comprising four 
drugs - rifampin, INH, pyrazinamide and 
ethambutol HCl) containing sodium ascorbate 
as one of the additives were powdered and 
an amount equivalent to about 100 mg of 
rifampin was accurately weighed into a dry 
100 mL volumetric flask. Ethyl acetate (70 
mL) was added and the flask shaken well. 
The volume was made up to 100 mL with 
ethyl acetate, mixed well, and then filtered 
through a 0.45 µ PTFE membrane filter. The 
filtrate (5 mL) was diluted to 25 mL with a 
diluent (pH 7.0 buffer/methanol, 60:40 v/v) in 
a 25 mL volumetric flask (Solution 3). Test 
solutions of 3-FDC (Solution 4) and 2-FDC 
(Solution 5) were similarly prepared as above 
using the applicable tablet powder containing 
sodium ascorbate as one of the additives.  
 
Preparation of Test Solution as per IP 
method (Solutions 6-8) 
 
Twenty tablets of 4-FDC containing sodium 
ascorbate as one of the additives were 
powdered and an amount equivalent to 40 
mg of rifampin was accurately weighed into a 
200 mL volumetric flask. The diluent (140 mL, 
pH 7.0 buffer: methanol, 60:40 v/v) was 
added, the flask shaken well and the volume 
was made up to 200ml with more of the 
diluents, and mixed well. The solution was 
filtered through a 0.45 µ PTFE membrane 
filter to give Solution 6. Test solutions of 3-
FDC (Solution 7) and 2-FDC (Solution 8) 
were similarly prepared using the applicable 
tablet powders containing sodium ascorbate 
as one of the additives.  
 
Preparation of spiked test solution as per 
proposed method (Solutions 9-11)  
 
Twenty tablets of 4-FDC containing sodium 
ascorbate as one of the additives were 
powdered and an amount equivalent to 100 
mg of rifampin was accurately weighed into a 
dry 100 mL volumetric flask. 3-
(isonicotinoylhydrazinomethyl) rifampicin (5 
mg) and 4 mg of rifampin quinone were 
transferred into this volumetric flask as well.  
Ethyl acetate (70 mL) was added and shaken 
well. The volume was made up to 100ml with 
ethyl acetate, mixed well and then filtered 
through a 0.45 µ PTFE membrane filter. The 
filtrate (5 mL) was diluted to 25 mL with 
diluent [pH 7.0 buffer: methanol, 60:40 v/v] in 
a 25 mL volumetric flask (Solution 9). Test 
solutions of 3-FDC (Solution 10) and 2-FDC 
(Solution 11) were similarly prepared using 
the applicable tablet powder containing 
sodium ascorbate as one of the additives.  
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Preparation of spiked test solution as per 
IP method (Solutions 12-14)  
 
Twenty tablets of 4-FDC containing sodium 
ascorbate as one of the additives were 
powdered and an amount equivalent to 40mg 
of rifampin was accurately weighed into a 200 
mL volumetric flask. 3-(isonicotinoyl-
hydrazinomethyl) rifampicin (2 mg) and 
1.8mg of rifampin quinone were transferred 
into this volumetric flask.  The diluent (140 
mL, pH 7.0 buffer: methanol, 60:40 v/v) was 
added and the flask shaken well. The volume 
was made up to 200 mL with more of the 
diluent, mixed well and then filtered through a 
0.45 µ PTFE membrane filter (Solution 12). 
Test solutions of 3-FDC (Solution 13) and 2-
FDC (Solution 14) were similarly prepared 
using the applicable tablet powders 
containing sodium ascorbate as one of the 
additives.  
 
Preparation of standard solution of 
rifampin quinone as per IP method 
(Solution 15)   
 
Rifampin quinone (1.8 mg) was dissolved and 
diluted to 200 mL with a diluent (pH 7.0 
buffer: methanol, 60:40 v/v) to obtain a 
solution of 8 µg/mL of rifampin quinone.  
 
Preparation of spiked solution of rifampin 
quinone in sodium ascorbate by IP 
method (Solution 16)  
 
Rifampin quinone (1.8 mg) and 1.3 mg 
sodium ascorbate were weighed accurately 
into a 200 mL volumetric flask. An amount 
(140mL) of a diluent (pH 7.0 buffer: methanol, 
60:40 v/v) was added and shaken well. The 
volume was made up to 200 mL with more of 
the diluent and mixed well. 
 
Chromatographic parameters  
 
For HPLC studies, a flow rate of 1.0 mL/min 
and detection wavelength of 254 nm was 
used. The sample injection volume was 20 µL 
and the column was maintained at ambient 
temperature of about 25 
0
C. The run time for 
each injection was 60 min. 
 
System suitability parameters 
 
In the chromatogram of system suitability 
solution, the resolution between 3-
(isonicotinoylhydrazinomethyl) rifampicin and 
rifampin quinone peaks should not be less 
than 4.0. Similarly, the resolution between 
rifampin quinone and rifampin peaks should 
not be less than 4.0. The %RSD of area 
under the curve (AUC) values of rifampin 
peak in six replicate injections of standard 




An aliquot (20 µL) of the prepared solutions 
(Solutions 1-16) were injected into the HPLC 





The data in Table 1 show that when the 
proposed solvent system was used for the 
extraction of the tablet sample, the rifampin 
quinone in the sample solution was stable. 
The difference in AUC value of the rifampin 
quinone peak at 3 h compared to the initial 
AUC value ranged between 0.3 and 2.1 %. 
The recovery (%) of rifampin quinone, using 
the proposed extraction solvent system (ethyl 
acetate), ranged between 99.0 and 101.1 %. 
 
The results in Table 2 show that rifampin 
quinone was converted very rapidly in the 
sample solution to rifampin in the presence of 
sodium ascorbate when the sample was 
prepared as per IP method. Rifampin quinone 
was not detected when the extraction solvent 
of IP method was used (see Table 2). 
However, when IP method extraction solvent 
was changed to ethyl acetate in the proposed 
method, the test solutions showed the 
presence of 1.15 (4-FDC), 1.52 (3-FDC) and 
1.60 % (2 FDC) of rifampin quinone 
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Table 1: Recovery and stability of rifampin quinone in ethyl acetate* 
 
Rifampin quinone    












99.00 99.39 99.02 
6 2.5 4.3 2.7 to to to 
9 5.2 8.7 5.6 100.12 101.14 99.65 
12 9.4 9.9 9.7    
* First dilution of test preparation was with ethyl acetate and second dilution with the diluent (pH 7.0 buffer: methanol 
(60:40); 
a  
% Difference = reduction in AUC value of rifampin quinone peak relative to initial AUC value; 
 b
 Value of 
recovery of rifampin quinone at initial analysis 
 
Table 2: Impurity and recovery data obtained as per International Pharmacopoeia (IP) and proposed 
methods 
 
 Impurity (%) 
 IP method             Proposed method 







Pure rifampin  Not detected 1.05 Not detected 1.10 
4-FDC tablet 1.59  Not Detected 1.63 1.15 
3-FDC tablet 0.89  Not Detected 0.90 1.52 
2-FDC tablet 0.85 Not Detected 0.89 1.60 
 Recovery of impurity from spiked sample (%) 
4-FDC ablet 101.89  Not Detected 98.80 99.95 
3-FDC Tablet 98.82  Not Detected 98.50 99.39 




Figure 1: (A) = Spiked sample of 4-FDC test 
solution prepared by International Pharmacopoeia 
(IP) method diluent (rifampin quinone 8 ppm + 
hydrazone 10 ppm spiked to sample); (B) = Spiked 
sample of 4-FDC test solution prepared by 
proposed method diluent (rifampin quinone 8 ppm 
+ hydrazone 10ppm spiked to sample  
 
To verify the suitability of the proposed 
method for the determination of hydrazone 
and rifampin quinone in 4-FDC, 3-FDC and 2-
FDC tablets containing sodium ascorbate as 
an additive, the proposed method was 
validated for these FDCs and the results of 
the method validation for 4-FDC tablets are 
presented in Table 3. The validation data, 
including specificity, linearity, range, 
accuracy, precision, robustness, limit of 
detection and solution stability were all within 




The International Pharmacopoeia (IP) 
method extraction solvent/diluent dissolves 
sodium ascorbate thus resulting in the 
conversion of rifampin quinone to rifampin in 
test sample preparations. The results show 
that the conversion of rifampin quinone to 
rifampin is so rapid that the chromatograms 
of the test preparations did not show any 
rifampin quinone peak when the solutions  
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   Table 3: Method validation data for 4-FDC tablets 
 
Parameter Hydrazone Rifampin quinone Acceptance criteria 
Specificity No interference  No interference  Interference should be 
NIL. 
Linearity (R) 1.000 1.000 >0.990 
Response factor 1.92 1.00 - 
Range 0.4 to 15.0 ppm 0.2 to 12.00 ppm - 







≤ 10 % 
≤ 10 % 
Robustness 
Change in flow rate  
Wavelength  




0.45 to 0.51 
 
0.65 to 0.68 
0.64 
0.72 to 0.77 
RRT ~ 0.5 (hydrazone  
& 0.6 (rifampin quinone) 
Limit of detection (LOD) 0.133 ppm 0.067 ppm - 
Solution stability
   
 (% Difference) 
a
 (% Difference) 
a
 ≤ 10 % 
After 3 h 0.4 1.0 
After 6 h 1.1 2.5 
After 9 h 1.3 5.2 
 After 12 h 1.9 9.4 
    a  
%
 




Figure 2:  (A) = rifampin quinone solution (8 ppm) 
prepared with International Pharmacopoeial method 
diluents; (B) = rifampin quinone solution (8ppm) 
spiked with sodium ascorbate 1.65 ppm 




were prepared as per the IP method (Figure 
2). It is worth noting that in the case of pure 
rifampin, recovery data for rifampin quinone 
were comparable for both IP method and the 
proposed method.  
 
Literature reports indicate that rifampin 
quinone is formed from rifampin by oxidation 
[7-9]. Many of the FDCs containing rifampin 
are likely to have sodium ascorbate as one of 
the additives to control the formation of 
rifampin quinone from rifampin in the tablet. 
The current International Pharmacopoeial 
method for estimation of rifampin-related 
substances in 4-FDC, 3-FDC and 2-FDC is 
unsuitable for the estimation of rifampin 
quinone in the FDCs containing sodium 
ascorbate as one of the additives since the 
solvent mixture of buffer and methanol used 





The developed method which entails a 
change in the solvent for the initial dilution of 
the FDC tablet samples containing sodium 
ascorbate as an additive would, unlike the IP 
method, lead to accurate quantitation of 
rifampin quinone and hydrazone impurity as 
evidenced by the results presented in this 
study. The developed method was 
successfully validated, is stability-indicating, 
and can be routinely used for the 
determination of hydrazone and rifampin 
quinone impurities in FDCs containing 
sodium ascorbate as an additive.  
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